Disseminated Intravascular Coagulation (DIC) Market: By Treatment (Medicines, Transfusions, Surgery, Others), By Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer, Others), By Route of Administration (Oral, Parenteral, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and Geography

The Disseminated Intravascular Coagulation (DIC) Market size was valued at USD 468.9 million in 2023 and is expected to grow at 3.8% CAGR over the forecast period 2023 – 2029. Disseminated Intravascular Coagulation (DIC) is a serious medical condition characterized by the abnormal and widespread activation of blood clotting mechanisms throughout the body. The DIC market pertains to the pharmaceutical and healthcare sectors focused on developing treatments, therapies, and diagnostic tools to address this life-threatening condition. DIC arises as a complication of various underlying conditions such as sepsis, trauma, cancer, and pregnancy-related complications, triggering a cascade of events that leads to the excessive formation of blood clots, eventually leading to organ damage and bleeding. According to the Centers for

Disease Control and Prevention (CDC), the prevalence of DIC varies depending on the underlying causes. For instance, in cases of severe sepsis, DIC can occur in up to 35% of patients. Sepsis-induced DIC has been associated with a mortality rate ranging from 30% to 80%. Additionally, DIC is a common complication in various malignancies, particularly acute promyelocytic leukemia (APML), where the incidence of DIC can reach 90% during the early stages of the disease. In pregnancies complicated by conditions like placental abruption and preeclampsia, the incidence of DIC can range from 1% to 12%, substantially increasing the risk of maternal and fetal complications. These statistics underscore the critical need for effective interventions and therapies within the DIC market to address the multifaceted challenges posed by this condition. Researchers, pharmaceutical companies, and healthcare providers continue to collaborate in developing innovative treatments and diagnostic tools to improve patient outcomes and reduce the morbidity and mortality associated with DIC.

Disseminated Intravascular Coagulation Market Key Developments: 

• In June 2022, LumiraDx expanded its cardiovascular testing portfolio with the CE marking of its NT-proBNP test and a new exclusion claim for its D-Dimer test. With its new Exclusion Claim, the LumiraDx D-Dimer test may be used at the point of care (POC) in conjunction with a clinical pre-test probability assessment model to allow clinicians to rule out venous thromboembolism (VTE) in symptomatic patients.